Clinical trials: Neuroendocrine (NE) Tumors

Neuroendocrine Tumors

Entinostat Neuroendocrine (NE) Tumor

• Terminated
• Age: 18 to 99 years
• Phase 2
• Results posted

This is an open-label, single arm, multi-center Phase II trial of entinostat given as a 5 mg oral dose every week (days 1, 8, 15, and 22 of a 4-week cycle) in patients with relapsed or refractory abdominal neuroendocrine (NE)…

Trial name

NCT03211988

Testing

Entinostat

Where

United States

Volunteers

5 people

Sponsor

Antonio Fojo